Related papers: Predicting erectile dysfunction after treatment fo…
Prostate cancer is a commonly diagnosed cancerous disease among men world-wide. Even with modern technology such as multi-parametric magnetic resonance tomography and guided biopsies, the process for diagnosing prostate cancer remains time…
Background. Real-world data show that approximately 50% of psoriasis patients treated with a biologic agent will discontinue the drug because of loss of efficacy. History of previous therapy with another biologic, female sex and obesity…
Cardiotoxicity related to cancer therapies has become a serious issue, diminishing cancer treatment outcomes and quality of life. Early detection of cancer patients at risk for cardiotoxicity before cardiotoxic treatments and providing…
Cancer progression involves the sequential accumulation of genetic alterations that cumulatively shape the tumour phenotype. In prostate cancer, tumours can follow divergent evolutionary trajectories that lead to distinct subtypes, but the…
Machine learning (ML) is a branch of Artificial Intelligence (AI) where computers analyze data and find patterns in the data. The study focuses on the detection of metastatic cancer using ML. Metastatic cancer is the point where the cancer…
Gleason grading of prostate cancer is an important prognostic factor but suffers from poor reproducibility, particularly among non-subspecialist pathologists. Although artificial intelligence (A.I.) tools have demonstrated Gleason grading…
Cancer is one of the most common diseases worldwide, posing a serious threat to human health and leading to the deaths of a large number of people. It was observed during the drug administration in chemotherapy that immune cells, cancer…
Oral cancer presents a formidable challenge in oncology, necessitating early diagnosis and accurate prognosis to enhance patient survival rates. Recent advancements in machine learning and data mining have revolutionized traditional…
Overall survival (OS) is the gold standard for assessing patient benefit and cost-effectiveness of new cancer drugs. However, it is often difficult to use OS as the primary endpoint in randomized clinical trials (RCTs) for patients with…
Prostate cancer (PCa) is the most frequently diagnosed malignancy in men and the eighth leading cause of cancer death worldwide. Multiparametric MRI (mpMRI) has become central to the diagnostic pathway for men at intermediate risk,…
Prostate cancer is the second most common form of cancer, though most patients have a positive prognosis with many experiencing long-term survival with current treatment options. Yet, each treatment carries varying levels of intensity and…
The majority of cancer treatments end in failure due to Intra-Tumor Heterogeneity (ITH). ITH in cancer is represented by clonal evolution where different sub-clones compete with each other for resources under conditions of Darwinian natural…
Introduction: The potential for multi-cancer early detection (MCED) tests to detect cancer at earlier stages is currently being evaluated in screening clinical trials. Once trial evidence becomes available, modelling will be necessary to…
The biggest Breast cancer is increasingly a major factor in female fatalities, overtaking heart disease. While genetic factors are important in the growth of breast cancer, new research indicates that environmental factors also play a…
With the advancement of treatment modalities in radiation therapy for cancer patients, outcomes have improved, but at the cost of increased treatment plan complexity and planning time. The accurate prediction of dose distributions would…
Despite the fact that cancer survivability rates vary greatly between stages, traditional survival prediction models have frequently been trained and assessed using examples from all combined phases of the disease. This method may result in…
Early detection of clinical outcomes such as cancer may be predicted based on longitudinal biomarker measurements. Tracking longitudinal biomarkers as a way to identify early disease onset may help to reduce mortality from diseases like…
Chronic diseases and cancer account for over 75 percent of healthcare costs in the US. Increased prevention services and improved primary care are thought to decrease costs. Current models for detecting changes in the health of populations…
The treatment of cancer is one of the most discussed issues in the realm of contemporary public health research. One of the primary concerns of both the general public and the government is the development of the most effective cancer…
The call for patient-focused drug development is loud and clear, as expressed in the 21st Century Cures Act and in recent guidelines and initiatives of regulatory agencies. Among the factors contributing to modernized drug development and…